Thymulin
Research OnlyAlso known as: FTS, Facteur Thymique Serique, Serum Thymic Factor, Thymulin Zinc Complex
A zinc-dependent nonapeptide hormone produced by thymic epithelial cells, discovered in 1977. Requires zinc binding for biological activity and plays a role in T-cell differentiation and immune regulation. While well-characterized biochemically, therapeutic development has been limited compared to other thymic peptides like thymosin alpha-1.
Research Statistics
Naturally occurring thymic nonapeptide (FTS) with international research body including US, European, and South American studies. Zinc-dependent T-cell differentiation mechanism is well-established as endogenous thymic hormone biology. Moderate human data; primarily research context without clinical approval.
Research Dossier
Overview
What is Thymulin and what does the research say?
Mechanism of Action
The proposed mechanisms of thymulin are based primarily on animal, in vitro, and limited human observational studies. Thymulin is unique among thymic hormones in requiring zinc for biological activity.
How It Works (Simplified)
Thymulin functions as a zinc-dependent immune modulator through several pathways:
Requires 1:1 zinc binding for biological activity. The zinc ion binds to serine and asparagine residues, creating the active metallopeptide conformation.
Promotes thymocyte maturation and CD4+/CD8+ differentiation. Enhances T-cell and NK cell function in thymus-deficient models.
Modulates IL-2, IFN-gamma, TNF-alpha, and IL-6 production. Reduces p38 MAPK phosphorylation and microglial activation in inflammatory states.
Interacts with hypothalamic-pituitary axis. Demonstrates bidirectional immune-neural communication and stress response integration.
Scientific Pathways
Zinc-Dependent Activation (Essential for Activity)
Thymulin (inactive apo-form) + Zn2+ → Thymulin-Zinc complex (active)
↓
Conformational change enables receptor bindingT-Cell Differentiation Pathway (Immune Modulation)
Thymulin-Zn → Thymic microenvironment → Immature thymocytes
↓
CD4+/CD8+ differentiation and maturationKey Research: Dardenne M et al. demonstrated the absolute zinc requirement for thymulin activity using NMR structural studies. PMID:6431950
Important Limitations
- Most therapeutic studies use thymulin analogs (PAT), not native thymulin
- Zinc status must be adequate for any thymulin effect
- Clinical efficacy trials are essentially absent
- Thymosin alpha-1 has far more clinical development and regulatory approvals
- Research activity has declined significantly since the 1990s
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on preclinical observations: Zinc-dependent activation occurs rapidly upon administration. Animal studies show early effects on T-cell markers within days. No human timeline data available for exogenous thymulin administration.
Animal studies suggest ongoing immune modulation effects. In zinc supplementation studies, restoration of thymulin activity observed within this timeframe. Analgesic effects in animal pain models noted within days to weeks.
Preclinical models show continued immune regulatory effects. Elderly zinc supplementation studies demonstrated sustained thymulin activity restoration over several weeks. Long-term effects on immune parameters observed.
Long-term animal and observational human studies suggest sustained effects when zinc status is maintained. However, human pharmacokinetics for exogenous thymulin, duration of effect, and optimal treatment protocols are completely unknown.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Thymulin product quality
Good Signs (7 indicators)
Warning Signs (6 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Thymulin with other peptides. Based on published research and mechanistic considerations.
Thymosin-Alpha-1
SynergisticBoth thymic peptides with complementary mechanisms. Thymosin alpha-1 has more clinical development and regulatory approvals. Thymulin's zinc-dependent activity may complement thymosin alpha-1's direct immune modulation. No direct clinical studies on combination.
Thymalin
SynergisticBoth derived from thymic tissue with overlapping immune modulatory effects. Thymalin is a bovine thymic extract while thymulin is a defined nonapeptide. May have additive effects on T-cell function.
Zinc-Supplements
SynergisticZinc is absolutely required for thymulin biological activity. Zinc deficiency abolishes thymulin function. Adequate zinc status is essential for any thymulin effect.
Thymogen
CompatibleBoth target T-cell differentiation through thymic pathways. Thymogen (L-Glu-L-Trp dipeptide) has a simpler structure. No known contraindications; theoretical complementary benefits.
BPC-157
CompatibleNon-overlapping mechanisms. Thymulin modulates immune function while BPC-157 focuses on tissue repair. Theoretical complementary benefits for immune-mediated recovery.
LL-37
CompatibleLL-37's antimicrobial and immunomodulatory properties may complement thymulin's T-cell modulatory effects. Both influence immune function through distinct pathways.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Thymulin
Related Peptides
Alpha-Defensins
HNP-1, HNP-2, HNP-3 +5 more
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val, Lysine-Proline-Valine, alpha-MSH(11-13) +1 more
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Kristagen
EDG, Glu-Asp-Gly, Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB, Lactoferricin B, LfcinB +1 more
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
Cathelicidin, hCAP18, Human Cationic Antimicrobial Peptide 18 +3 more
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Murepavadin
POL7080, RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.